There has been increasing interest in exploring additional means to detect chemotherapy-induced myocardial injury such as monitoring serum biomarkers that are indicative of cardiac injury (e.g., cardiac troponin I (cTnI) and cardiac troponin T (cTnT), myoglobin, fatty acid binding protein 3 (FABP3), and creatine kinase) and/or heart failure (B-type natriuretic peptide [BNP]; Gaze and Collinson 2005; Force and Kolaja 2011). Here, TNNI3 is linked to heart failure.